Compare Recursion Pharmaceuticals Inc (RXRX) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Xcel Energy Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $4.07 (market cap $2.14B), while Xcel Energy Inc trades at $73.13 (market cap $45.82B). The key difference: Xcel Energy Inc is far larger — about 21.4× Recursion Pharmaceuticals Inc's market cap, and Xcel Energy Inc pays a 3.23% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Xcel Energy Inc for 61 Days on average.
| RXRX | XEL | |
|---|---|---|
Market Cap | $2.14B | $45.82B |
Volume | 30,789,535 | 6,910,516 |
Sector | Health | Utilities |
52-Week High | $6.79 | $83.91 |
52-Week Low | $2.84 | $69.39 |
Typical Hold Time | 22 Days | 61 Days |
Enterprise Value | $1.66B | $84.14B |
Dividend Yield | — | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Xcel Energy (XEL) trades at $72.42, down 0.43% with a bearish technical signal despite recent earnings beats. The stock shows solid fundamentals with $14.67B revenue, 15.28% net margin, and consistent cash flow growth. Analyst consensus is bullish with a $90.83 price target (62.96% buy rating), while institutional activity shows mixed positioning. Recent news highlights data center power demand growth and wildfire liability concerns.
XEL offers attractive utility exposure with 11% rate base growth potential and dividend stability, but faces regulatory and wildfire litigation risks. The current valuation at 20.1x P/E appears reasonable given earnings trajectory, though technical weakness near support at $71-72 requires monitoring for entry points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
